



Anthony D. Sabatelli, Ph.D.

PATENT COUNSEL

asabatelli@wiggin.com

New Haven: +1 203 498 4365

Anthony is Patent Counsel in Wiggin and Dana's Corporate Department, where he focuses his practice in the Intellectual Property and Life Sciences Practice Groups. He is a former business executive with both in-house corporate and law firm experience, with specific expertise in biotechnology. Anthony is a seasoned intellectual property attorney, and he is well-versed in patent and Hatch-Waxman and regulatory law. He began his career as a research scientist and project manager, and he is an inventor on numerous patents.

Although Anthony focuses his patent practice on the life sciences, his patent experience covers a broad array of technologies, including pharmaceuticals, small molecules, macromolecules, RNA and DNA, proteins, biotechnology, drug delivery systems, inorganic chemistry and metals, medical devices, polymers, personal care products, formulations, process chemistry, X-ray crystallography, mechanical devices, green chemistry, software, nanotechnology, analytical methods, research tools, and blockchain technology. The insightful, practical, and business-oriented service he provides to his clients include, patent preparation and prosecution, foreign patent prosecution, patent searching and interpretation, patentability opinions, freedom-of-operation opinions, and landscape and competitive intelligence analyses. Additionally, Anthony has helped his clients build and manage their portfolios through patent life cycle management and time-line projection tools.

Anthony frequently writes and speaks on a range of topics, including developments in patent subject matter eligibility (35 USC § 101), the microbiome, nanotechnology, oncology, green chemistry, energy issues, the intersection of patent and regulatory law, and scientific analytical tools for supporting patent litigation. He has testified at public hearings at the US Patent and Trademark Office on patent subject matter eligibility and is a regular guest contributor to Patent Docs, www.patentdocs.com, a Patent Law Weblog that publishes on a broad range of patent topics.

He is an avid supporter of the bioscience industry. Anthony is an active member of BioCT, the advocacy organization for the industry where he has served as a former director and also former chair of its government advocacy committee, where he has testified at the state level on issues relevant to the industry and public health.

Before joining Wiggin and Dana, Anthony was Partner and Chair of the Biotech and Life Sciences Practice at a boutique law firm. Previously, Anthony was Vice President and General Counsel and Chief Patent Counsel at

Melinta Therapeutics, Inc. Prior to this, he was Assistant Counsel at Merck & Co., Inc. and Patent Counsel at Procter & Gamble.

Anthony received his J.D., *cum laude*, from the Salmon P. Chase College of Law. He received his Ph.D., with Honors, in Organic Chemistry from Yale University, and his B.S., *summa cum laude*, in Chemistry from Fairfield University.

Education

- Salmon P. Chase College of Law (J.D., 1994)
 - cum laude
- Yale University (Ph.D., 1984)
 - With Honors
- Fairfield University (B.S., 1979)
 - summa cum laude

Bar Admissions

- U.S. Patent and Trademark Office
- Ohio

Memberships and Affiliations

- BioCT
 - Former Board of Directors
 - Government Affairs Committee (January 2015 to present)
 - Member (2011-present)
- Yale Alumni Association
 - Board of Governors (July 2016 to present)
 - Past Chair, Executive Board Graduate School Alumni Association
- Yale Alumni Fund
 - Board Member (July 2018 to present)
- Nicholas & Viola Spinelli Educational Foundation
 - Vice President and Director (October 2016 to present)

Experience

- Was one of ten speakers invited to testify before the US Patent & Trademark Office at the May 2014 public forum on the Guidance for patent eligible subject matter.
- Designed, built, and managed a patent estate for a biotechnology company comprising a worldwide portfolio of several hundred patents.
- Was an integral member of the senior management team of a biotechnology company which raised over \$250 million in venture financing, and which in-licensed and progressed a novel antibiotic into Phase 3 clinical trials.
- Led an interdepartmental company team that worked closely with its US Senator's office on the passage of the 2012 Generating Antibiotic Incentives Now (GAIN) legislation, which provides important exclusivity and regulatory incentives for companies to develop new antibiotics for treating serious infections.
- Built the underlying patent estate for a new chemical class of drugs for a research collaboration with a major pharmaceutical company in the area of infectious disease.
- Had worldwide patent portfolio responsibility at a major pharmaceutical company for their billion-dollar bone biology franchise, where he implemented a comprehensive patent life cycle management strategy for the franchise's flagship drug.
- Successfully completed an over-seas assignment at a major consumer products company where he provided legal counsel for the Asia-Pacific product managers and trained the newly-hired patent staff.
- As a product development manager at a major consumer products company led the reformulation of their sunscreen line, resulting in successful national expansion of the line.